Allogeneic hematopoietic stem cell transplantation (HSCT) has advanced to a common
procedure for treating also older patients with malignancies and immunodeficiency …

Umbilical cord blood (UCB) is an important source of hematopoietic stem cells (HSC) for
allogeneic transplantation when HLA-matched sibling and unrelated donors (MUD) are …

Background Viral reactivations (VRs) after hematopoietic cell transplantation (HCT)
contribute to significant morbidity and mortality. Timely immune reconstitution (IR) is …

Hematopoietic stem cell transplantation (HSCT) is the definitive cure for many malignant and
nonmalignant diseases. However, delays in immune reconstitution (IR) following HSCT …

We have piloted a low-dose schedule of 5-azacytidine followed by donor lymphocyte
infusions (DLIs) in patients with relapse of AML or chronic myelomonocytic leukemia …

For patients with acute myeloid leukemia (AML) relapsed after allogeneic bone marrow
transplantation (BMT), donor leukocyte infusion (DLI) as sole therapy has very limited …

Donor T cells play a pivotal role in the graft-versus-tumor effect after allogeneic
hematopoietic stem cell transplantation. Regulatory T cells (Tregs) may reduce alloreactivity …

Haploidentical hematopoietic stem cell transplantation is a curative alternative option for
patients without an otherwise suitable stem cell donor. In order to prevent graft‐versus‐host …

Juvenile myelomonocytic leukemia (JMML) is a clonal myeloproliferative disorder of early
childhood. In all, 21 patients with JMML who received donor leukocyte infusion (DLI) after …

Donor leukocyte infusion (DLI) alone has very limited efficacy for patients with acute
lymphoblastic leukemia (ALL) who have relapsed after allogeneic bone marrow …